From this combination, SL-401 or tagraxofusp was generated, which reached phase II clinical evaluation, demonstrating a strong activity especially in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy that rapidly evolves to a leukemia phase and whose blasts overexpress IL-3R [40]. This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.